AAP
DSGN icon

Arax Advisory Partners’s Design Therapeutics DSGN Stock Holding History

Arax Advisory Partners’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.61K Buy
+180
New +$2.24K ﹤0.01% 4758
2026
Q1 		– Sell
-47
Closed -$441 – 3941
2025
Q4 		$441 Sell
47
-147
-76% -$1.15K ﹤0.01% 3630
2025
Q3 		$1.46K Buy
+194
New +$972 ﹤0.01% 3173
2025
Q1 		– Sell
-143
Closed -$883 – 2771
2024
Q4 		$883 Sell
143
-101
-41% -$585 ﹤0.01% 2200
2024
Q3 		$1.31K Hold
244
– – ﹤0.01% 2176
2024
Q2 		$818 Buy
+244
New +$951 ﹤0.01% 2231

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Arax Advisory Partners's DSGN Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Design Therapeutics (DSGN) in Q2 2026: 180 shares worth $2.61K. The stake represents ﹤0.01% of the portfolio and ranks #4758 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in DSGN as recently as Q4 2025.

Arax Advisory Partners first reported a position in DSGN in Q2 2024 and has held it in 6 quarters since. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Arax Advisory Partners held 180 shares of Design Therapeutics worth $2.61K as of Q2 2026.
  • Design Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Design Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4758 holding.
  • Arax Advisory Partners first reported a position in Design Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.